PTEN opposes negative selection and enables oncogenic transformation of pre-B cells
View abstract on PubMed
Summary
This summary is machine-generated.Loss of phosphatase and tensin homolog (PTEN) in pre-B acute lymphoblastic leukemia (ALL) cells caused rapid cell death, unlike its tumor-suppressive role in other cancers. This suggests PTEN inhibition as a novel strategy for overcoming ALL drug resistance.
Area Of Science
- Oncology
- Molecular Biology
- Immunology
Background
- Phosphatase and tensin homolog (PTEN) is a critical tumor suppressor and negative regulator of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway.
- PTEN's established tumor-suppressive functions in various cancers contrast with its unexplored role in pre-B acute lymphoblastic leukemia (ALL).
Purpose Of The Study
- To investigate the role of PTEN in pre-B ALL pathogenesis and explore its potential as a therapeutic target.
- To determine the consequences of PTEN loss or inhibition in pre-B ALL cells.
Main Methods
- Cre-mediated deletion of Pten in mouse models of pre-B ALL.
- Small-molecule inhibition of PTEN in human pre-B ALL cell lines.
- Analysis of AKT signaling, p53 activation, and cell death pathways.
Main Results
- Loss of PTEN alleles in mouse models led to rapid pre-B ALL cell death and leukemia clearance.
- PTEN inhibition in human pre-B ALL cells caused AKT hyperactivation, p53 checkpoint activation, and cell death.
- PTEN loss functionally mimicked autoreactive pre-B cell receptor signaling, triggering a deletional checkpoint.
Conclusions
- Contrary to its role in other cancers, PTEN loss is detrimental to pre-B ALL cells, inducing cell death via AKT hyperactivation and p53 signaling.
- Targeted PTEN inhibition represents a novel therapeutic strategy for overcoming drug resistance in human ALL by activating autoreactive B cell elimination checkpoints.